期刊
SIGNAL TRANSDUCTION AND TARGETED THERAPY
卷 7, 期 1, 页码 -出版社
SPRINGERNATURE
DOI: 10.1038/s41392-022-00947-7
关键词
-
资金
- National Natural Science Foundation of China, China [82073402]
Antibody-drug conjugates (ADCs) combine the highly specific targeting ability of monoclonal antibodies with the potent killing effect of cytotoxic drugs to accurately and efficiently eliminate cancer cells. Since the approval of the first ADC in 2000, 14 ADCs have been marketed worldwide, with over 100 ADC candidates currently in clinical trials. These novel cancer therapeutics, known as biological missiles, are leading the way in targeted cancer therapy.
Antibody-drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of cancer cells, which has become one of the hotspots for the research and development of anticancer drugs. Since the first ADC, Mylotarg(R) (gemtuzumab ozogamicin), was approved in 2000 by the US Food and Drug Administration (FDA), there have been 14 ADCs received market approval so far worldwide. Moreover, over 100 ADC candidates have been investigated in clinical stages at present. This kind of new anti-cancer drugs, known as biological missiles, is leading a new era of targeted cancer therapy. Herein, we conducted a review of the history and general mechanism of action of ADCs, and then briefly discussed the molecular aspects of key components of ADCs and the mechanisms by which these key factors influence the activities of ADCs. Moreover, we also reviewed the approved ADCs and other promising candidates in phase-3 clinical trials and discuss the current challenges and future perspectives for the development of next generations, which provide insights for the research and development of novel cancer therapeutics using ADCs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据